Regulus Therapeutics
San Diego, United States
46 employees
Post-IPO Equity
Total: $480.90M
Biotechnology, Health Care +1
General Information
San Diego, United States
BounceWatch is an independent company data service, not affiliated with Regulus Therapeutics. To contact Regulus Therapeutics, visit regulusrx.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Regulus Therapeutics compare?
A PDF of Regulus Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Regulus Therapeutics soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Regulus Therapeutics on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
United States Market
Biotechnology
About Regulus Therapeutics
Business keywords: biopharmaceutical, drug discovery, microRNA therapeutics, oligonucleotide, biomarkers, intellectual property, San Diego, executive team, scientific advisory board, life sciences, microRNA research, gene expression, innovation
Funding Rounds & Investors (15)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | $100.00M | 7 |
|
12 Mar 2024 |
| Post IPO Equity | $15.00M | 2 |
|
13 Apr 2023 |
| Post IPO Equity | $4.50M | - |
|
10 Nov 2022 |
| Post IPO Equity | $34.60M | 2 |
|
24 Nov 2021 |
| Post IPO Equity | $19.40M | - |
|
08 Dec 2020 |
| Post IPO Equity | $16.70M | - |
|
07 May 2019 |
| Post IPO Equity | $43.00M | - |
|
19 Jul 2017 |
| Post IPO Equity | Undisclosed | 1 |
|
01 Jan 2017 |
| Post IPO Debt | $30.00M | 1 |
Oxford Finance LLC
|
20 Jun 2016 |
| Post IPO Equity | $103.50M | - |
|
27 Oct 2014 |
Regulus Therapeutics Alternatives & Competitors
View All Alternatives
Solving fundamental problems in drug discovery to create a new generation of therapeutics.
Accelerating the path from AI-driven design to physical biology.
Developing innovative precision therapies for the treatment of inflammatory and fibrotic diseases
FAQ About Regulus Therapeutics
Source: BounceWatch company record for Regulus Therapeutics, https://bouncewatch.com/company/regulus-therapeutics, updated 25 November 2024. When citing, please name BounceWatch and link this page.
